ZIMLAB

Zim Laboratories financials

Market cap
₹579 Cr
Sector
Healthcare
Calls analysed
6
Latest concall · Q1 FY27 · call held 07 Aug 2026

Zim Laboratories Limited Q1 FY27

EBITDA 34 million EBITDA Margin 3.7% Profit After Tax -40 million

What went well

  • Total operating income grew 31.2% YoY to INR 942 million.
  • Exports remained resilient, contributing 84% of total operating income.
  • New innovative product portfolio and oral insulin business returned to normalized contribution of 18% of revenue.

What to watch

  • EBITDA margin stood at 3.7% (INR 34 million), impacted by planned investments and higher costs.
  • Profit after tax was negative INR 40 million, compared to negative INR 19 million in the prior year.
Read the full call →

What Zim Laboratories Limited does

Zim Laboratories develops, manufactures and supplies differentiated and complex generic pharmaceutical products in oral solid dosage forms, built on proprietary, non-infringing novel drug delivery technologies (NDDS). Its Pharmaceuticals division makes Pre-Formulation Intermediates, Finished Formulations, Oral Thin Films (OTF) and New Innovative Products (NIP) sold into regulated, pharmerging and RoW markets, while its Nutraceuticals division supplies vitamins, healthcare and dietary supplements. Manufacturing is carried out across three facilities in Nagpur, Maharashtra, supported by an in-house R&D team that develops the company's proprietary technology platforms.

Segments

  • Pharmaceuticals
  • Nutraceuticals
Manufacturing facilities
3 in Nagpur — Solid Oral Dosage (General) 1,00,000 sq.ft, Solid Oral Dosage (Cephalosporin) 16,000 sq.ft, Oral Thin Film 6,300 sq.ft
Production utilisation rate
65%
Marketing Authorisations received (cumulative)
34 (NIP 5, OTF 25, FF 4)
Regulatory filings completed (cumulative)
57 (NIP 14, OTF 29, FF 14)
Proprietary technology platforms
4 non-infringing platforms
Therapy segments covered
7
Founded 1989Headquarters Nagpur, Maharashtra, India Company website

Guidance record · Q1 FY27

what the last two calls moved 16 tracked 3 delivered 2 missed 11 open
  • EU-GMP Reinspection / Audit Completion delivered said Q1 FY26 Promised: within the next 6 months Q1 FY27: Promise previously achieved in Q4 FY26.
  • NIP and OTF contribution to total turnover missed said Q4 FY25 Promised: 30% to 40% going forward Q1 FY27: Dropped to 18% for the quarter, described as a 'normalized' level. Still significantly below the 30-40% target.
  • EBITDA Margin at risk said Q4 FY25 Promised: 15% - 17% by FY26-27 Q1 FY27: Dropped to 3.7% for the quarter. Management now guides for mid-teens in FY28, contingent on EU-GMP, pushing out the timeline.

All 16 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 30.3%, net profit down 129.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue90 95 109 71 88 −1%108 +13%103 −5%93 +30%
EBITDA8 12 15 4 6 −26%13 +6%7 −57%2 −45%
Net profit1 4 5 -2 0 −90%4 −2%3 −39%-4 −130%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +85.8% 1Y

₹60₹80₹100₹120₹140Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 17 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 20 May 2026Q1 FY27 — 7 Aug 2026

1Y: ₹74.94 on 10 Sept 2025 → ₹139.22. High ₹139.22 (11 Sept 2026), low ₹60.26 (30 Mar 2026).

How the price took the results

close before → close after

Q1 FY27
−2.8%
7 Aug
Q4 FY26
−1.5%
20 May
Q3 FY26
−4.8%
13 Feb
Q2 FY26
−1.9%
17 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue fell 2.3% a year over 3 years, FY23 to FY26. Operating margin narrowed to 8.0%.

Year endingFY23FY24FY25FY26
Revenue₹398 Cr₹365 Cr₹376 Cr₹370 Cr
Operating profit₹52 Cr₹40 Cr₹43 Cr₹30 Cr
Operating margin13.0%11.0%11.5%8.0%
Interest₹6 Cr₹7 Cr₹11 Cr₹13 Cr
Depreciation₹17 Cr₹15 Cr₹20 Cr₹19 Cr
Net profit₹24 Cr₹17 Cr₹12 Cr₹6 Cr
Net margin6.1%4.6%3.1%1.6%
Cash from operations₹35 Cr₹11 Cr₹51 Cr₹48 Cr
Free cash flow₹0 Cr₹-61 Cr₹13 Cr₹12 Cr
ROCE17.0%10.0%8.0%5.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹16 Cr₹16 Cr₹49 Cr₹49 Cr₹49 Cr₹54 Cr
Reserves₹141 Cr₹154 Cr₹145 Cr₹183 Cr₹203 Cr₹233 Cr
Borrowings₹82 Cr₹53 Cr₹62 Cr₹112 Cr₹121 Cr₹127 Cr
Other liabilities₹81 Cr₹112 Cr₹79 Cr₹99 Cr₹94 Cr₹112 Cr
Total liabilities₹320 Cr₹335 Cr₹335 Cr₹443 Cr₹467 Cr₹525 Cr
Fixed assets₹103 Cr₹103 Cr₹107 Cr₹160 Cr₹187 Cr₹160 Cr
Capital work in progress₹10 Cr₹11 Cr₹26 Cr₹40 Cr₹46 Cr₹89 Cr
Investments₹8 Cr₹8 Cr₹8 Cr₹8 Cr₹0 Cr₹18 Cr
Other assets₹199 Cr₹213 Cr₹193 Cr₹234 Cr₹234 Cr₹258 Cr
Total assets₹320 Cr₹335 Cr₹335 Cr₹443 Cr₹467 Cr₹525 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters trimmed −2.90 pp while the public added +1.82 pp. The shareholder count shrank 13% to 14,510.

Promoters
30.4%
FIIs
0.0%
DIIs
1.3%
Public
68.3%

Since Jun 2025

  • Promoters −2.90 pp
  • Public +1.82 pp
  • DIIs +1.10 pp

How it drifted, 12 quarters

Over this window promoters fell from 33.3% to 30.4% — −2.9 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 33.3%, Public 66.8%.Dec '23: Promoters 33.3%, Public 66.7%.Mar '24: Promoters 33.3%, FIIs 0.0%, Public 66.7%.Jun '24: Promoters 33.3%, Public 66.7%.Sep '24: Promoters 33.3%, Public 66.7%.Dec '24: Promoters 33.3%, FIIs 0.2%, DIIs 0.2%, Public 66.3%.Mar '25: Promoters 33.3%, FIIs 0.0%, DIIs 0.2%, Public 66.5%.Jun '25: Promoters 33.3%, FIIs 0.0%, DIIs 0.2%, Public 66.5%.Sep '25: Promoters 33.3%, DIIs 0.2%, Public 66.5%.Dec '25: Promoters 33.3%, FIIs 0.0%, DIIs 0.2%, Public 66.5%.Mar '26: Promoters 30.4%, DIIs 0.1%, Public 69.6%.Jun '26: Promoters 30.4%, FIIs 0.0%, DIIs 1.3%, Public 68.3%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Zim Laboratories Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Anwar Siraj Daud 25.07%+0.14 pp
Elimath Advisors Private Limited 10.43%unchanged
Zakir S Vali 9.43%unchanged
Florintree Trinex Llp 8.90%unchanged
Investor Education And Protection Fund Authority Ministry Of Corporate Affairs 3.58%unchanged
Sabbah Zulfiquar Kamal 2.80%unchanged
Bonanza Business Services Pvt Ltd 2.32%unchanged
Dr Iguer Abdelmounaim 2.18%unchanged
Zulfiquar Kamal 2.08%−0.15 pp
Laadki Trading And Investments Limited 1.23%unchanged
Jyoti Bharat Sheth 1.23%unchanged
Tata India Pharma & Healthcare Fund Mutual fund1.07%newly disclosed

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

All earnings calls (6)

Read the Q1 FY27 call →

Learn to analyse Zim Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.